Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension

波生坦 医学 肺动脉高压 结缔组织病 CTD公司 内科学 心脏病学 观察研究 随机对照试验 队列研究 疾病 内皮素受体 自身免疫性疾病 地质学 受体 海洋学
作者
Christopher J. Valerio,Clive E Handler,Peter Kabunga,Colette J Smith,Christopher Paul Denton,Gerry Coghlan
出处
期刊:Rheumatology [Oxford University Press]
卷期号:49 (11): 2147-2153 被引量:16
标识
DOI:10.1093/rheumatology/keq241
摘要

OBJECTIVES: To report outcomes in patients with CTD-pulmonary arterial hypertension (CTD-PAH) in an observational cohort treated with bosentan or sitaxentan and determine whether differences would justify a randomized, controlled multicentre study in this subpopulation. METHODS: Patients with CTD-PAH, diagnosed by right-heart catheter studies, were assigned to either bosentan or sitaxentan based on physician choice. All patients were followed up with repeat assessments and data were collected for the local registry database. RESULTS: The bosentan- (n = 32) and sitaxentan- (n = 22) treated groups had comparable haemodynamic and prognostic measures at baseline. Repeat haemodynamic assessments showed reductions in pulmonary vascular resistance with bosentan (-99 dynes/s/cm(5), P < 0.01) and sitaxentan (-92 dynes/s/cm(5), P < 0.05). The 6-min walk distance improved at 3 months with sitaxentan (25 m, P < 0.05). N-terminal pro-B-type natriuretic peptide levels fell in the bosentan cohort at 6 months (-70 pmol/l, P < 0.05) and 1 year (-83 pmol/l, P < 0.01). Haemoglobin fell with both drugs (at 3 months -0.5 g/dl bosentan, P < 0.05 and -0.9 g/dl sitaxentan, P < 0.005). Calculations of the difference in treatment effect did not demonstrate superiority of either therapy. The 1-year estimated clinical worsening event rates were high: 41% sitaxentan, 62% bosentan (P = 0.142), with serious event rates of 27 and 14% (P = 0.263, log-rank test), respectively. Six patients discontinued bosentan because of transaminase elevation within the first year. Estimated 1-year survival was similar in both groups and 96% overall. CONCLUSION: Both sitaxentan and bosentan appear effective in CTD-PAH, but the apparent additional benefit of sitaxentan reported from the open-label Sitaxentan To Relieve ImpaireD Exercise-2X study was not confirmed in this observational cohort. Although survival has improved, event rates continue to be substantial and CTD-PAH remains a therapeutic challenge.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
隐形曼青的应助被学止境采纳,获得50
1秒前
Auoroa完成签到,获得积分10
1秒前
缥缈安荷完成签到,获得积分10
1秒前
LL发布了新的文献求助10
1秒前
YZ发布了新的文献求助10
1秒前
科研通AI6.3的应助被renyun采纳,获得10
2秒前
2秒前
4秒前
4秒前
科研小白完成签到,获得积分10
5秒前
5秒前
syvshc的应助被天真的访文采纳,获得10
6秒前
7秒前
充电宝的应助被chenzhaoyang采纳,获得10
7秒前
7秒前
7秒前
黑米粥发布了新的文献求助200
8秒前
123完成签到,获得积分10
8秒前
ff完成签到 ,获得积分10
8秒前
9秒前
9秒前
ywd完成签到,获得积分10
9秒前
Hello的应助被包容河马采纳,获得10
9秒前
CipherSage的应助被聪明甜桃采纳,获得10
9秒前
10秒前
Lucas的应助被wyc采纳,获得10
10秒前
根本没有的事完成签到 ,获得积分10
11秒前
默默的迎南完成签到,获得积分10
11秒前
月月完成签到,获得积分10
11秒前
11秒前
11秒前
11秒前
wooo发布了新的文献求助10
12秒前
13秒前
Pengzhuhuai发布了新的文献求助10
14秒前
Benjamin完成签到 ,获得积分20
14秒前
元狩发布了新的文献求助10
14秒前
Flong完成签到,获得积分10
14秒前
liu发布了新的文献求助30
14秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178449
求助须知:如何正确求助?哪些是违规求助? 9569267
关于积分的说明 21803160
捐赠科研通 7773332
什么是DOI,文献DOI怎么找? 3432799
关于科研通互助平台的介绍 2556833
邀请新用户注册赠送积分活动 2478436